Page last updated: 2024-08-16

resveratrol and exenatide

resveratrol has been researched along with exenatide in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Hardy, DB; Ma, N	1
Dash, S; Lewis, GF; Morgantini, C; Xiao, C	1
Hong, SW; Kim, MJ; Kwon, H; Lee, J; Lee, WY; Park, SE; Rhee, EJ	1

Reviews

2 review(s) available for resveratrol and exenatide

Article	Year
The fetal origins of the metabolic syndrome: can we intervene? Journal of pregnancy, 2012, Volume: 2012 Topics: Antioxidants; Ascorbic Acid; Diet Therapy; Dietary Supplements; Exenatide; Fatty Acids, Omega-3; Female; Fetal Growth Retardation; Folic Acid; Humans; Hypoglycemic Agents; Melatonin; Metabolic Syndrome; Micronutrients; Peptides; Pregnancy; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Resveratrol; Stilbenes; Venoms	2012
New and emerging regulators of intestinal lipoprotein secretion. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Animals; Apolipoprotein B-100; Apolipoprotein B-48; Atherosclerosis; Bile Acids and Salts; Cholesterol; Chylomicrons; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Dyslipidemias; Exenatide; Fatty Acids, Nonesterified; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Insulin; Insulin Resistance; Intestine, Small; Lipoproteins; Microbiota; Peptides; Receptors, Glucagon; Resveratrol; Secretory Rate; Stilbenes; Triglycerides; Venoms	2014

Article

Year

The fetal origins of the metabolic syndrome: can we intervene?

Journal of pregnancy, 2012, Volume: 2012

Topics: Antioxidants; Ascorbic Acid; Diet Therapy; Dietary Supplements; Exenatide; Fatty Acids, Omega-3; Female; Fetal Growth Retardation; Folic Acid; Humans; Hypoglycemic Agents; Melatonin; Metabolic Syndrome; Micronutrients; Peptides; Pregnancy; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Resveratrol; Stilbenes; Venoms

2012

New and emerging regulators of intestinal lipoprotein secretion.

Atherosclerosis, 2014, Volume: 233, Issue:2

Topics: Animals; Apolipoprotein B-100; Apolipoprotein B-48; Atherosclerosis; Bile Acids and Salts; Cholesterol; Chylomicrons; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Dyslipidemias; Exenatide; Fatty Acids, Nonesterified; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Insulin; Insulin Resistance; Intestine, Small; Lipoproteins; Microbiota; Peptides; Receptors, Glucagon; Resveratrol; Secretory Rate; Stilbenes; Triglycerides; Venoms

2014

Other Studies

1 other study(ies) available for resveratrol and exenatide

Article	Year
Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling. Biochemical and biophysical research communications, 2020, 09-17, Volume: 530, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Enzyme Activators; Exenatide; Metformin; Muscle, Smooth, Vascular; Phosphates; RANK Ligand; Rats; Resveratrol; Signal Transduction; Vascular Calcification	2020

Article

Year

Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling.

Biochemical and biophysical research communications, 2020, 09-17, Volume: 530, Issue:2

Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Enzyme Activators; Exenatide; Metformin; Muscle, Smooth, Vascular; Phosphates; RANK Ligand; Rats; Resveratrol; Signal Transduction; Vascular Calcification

2020